| Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority … RA Nout, V Smit, H Putter, IM Juergenliemk-Schulz, JJ Jobsen, L Lutgens, ... The Lancet 375 (9717), 816-823, 2010 | 1326 | 2010 |
| KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas VT Smit, AJM Boot, AMM Smits, GJ Fleuren, CJ Cornelisse, JL Bos Nucleic acids research 16 (16), 7773-7782, 1988 | 816 | 1988 |
| Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts E Stelloo, RA Nout, EM Osse, IJ Jürgenliemk-Schulz, JJ Jobsen, ... Clinical cancer research 22 (16), 4215-4224, 2016 | 702 | 2016 |
| Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 19 (3), 295-309, 2018 | 566 | 2018 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 519 | 2020 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 434 | 2015 |
| Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 20 (9), 1273-1285, 2019 | 401 | 2019 |
| Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. AM Bunt, J Hermans, VT Smit, CJ Van de Velde, GJ Fleuren, JA Bruijn Journal of clinical oncology 13 (1), 19-25, 1995 | 361 | 1995 |
| Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer–a pooled analysis of PORTEC 1 and 2 trials T Bosse, EEM Peters, CL Creutzberg, IM Jürgenliemk-Schulz, JJ Jobsen, ... European journal of cancer 51 (13), 1742-1750, 2015 | 354 | 2015 |
| Near‐infrared fluorescence‐guided resection of colorectal liver metastases JR van der Vorst, BE Schaafsma, M Hutteman, FPR Verbeek, GJ Liefers, ... Cancer 119 (18), 3411-3418, 2013 | 342 | 2013 |
| Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial RA Nout, H Putter, IM Jürgenliemk-Schulz, JJ Jobsen, LCHW Lutgens, ... Journal of Clinical Oncology 27 (21), 3547-3556, 2009 | 340 | 2009 |
| Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients EM de Kruijf, JGH van Nes, CJH van de Velde, H Putter, VT Smit, ... Breast cancer research and treatment 125, 687-696, 2011 | 335 | 2011 |
| Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer JSD Mieog, SL Troyan, M Hutteman, KJ Donohoe, JR Van Der Vorst, ... Annals of surgical oncology 18, 2483-2491, 2011 | 322 | 2011 |
| HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients EM de Kruijf, A Sajet, JGH van Nes, R Natanov, H Putter, VT Smit, ... The Journal of Immunology 185 (12), 7452-7459, 2010 | 320 | 2010 |
| Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review AN Scholten, WLJ van Putten, H Beerman, VT Smit, PCM Koper, ... International Journal of Radiation Oncology* Biology* Physics 63 (3), 834-838, 2005 | 320 | 2005 |
| Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer DN Church, E Stelloo, RA Nout, N Valtcheva, J Depreeuw, N Ter Haar, ... Journal of the National Cancer Institute 107 (1), dju402, 2015 | 319 | 2015 |
| POLE proofreading mutations elicit an antitumor immune response in endometrial cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 303 | 2015 |
| Accuracy in diagnosis of celiac disease without biopsies in clinical practice KJ Werkstetter, IR Korponay-Szabó, A Popp, V Villanacci, M Salemme, ... Gastroenterology 153 (4), 924-935, 2017 | 293 | 2017 |
| A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer CES Hoogstins, QRJG Tummers, KN Gaarenstroom, CD De Kroon, ... Clinical Cancer Research 22 (12), 2929-2938, 2016 | 262 | 2016 |
| Clinicopathological and molecular characterisation of ‘multiple‐classifier’endometrial carcinomas A León‐Castillo, E Gilvazquez, R Nout, VT Smit, JN McAlpine, ... The Journal of pathology 250 (3), 312-322, 2020 | 259 | 2020 |
